GMP Closeout "Carrots" Sprout; Baxter Receives First, But FDA Is Subdued
Executive Summary
If the first-ever FDA closeout letter to an Rx manufacturer is any indication, the correspondence may not offer a clear-cut end to compliance issues cited in warning letters
You may also be interested in...
FDA Policy Power Challenged In House Questions On Untitled Letters
Chairman Murphy wants to know if FDA is aware of consequences of publishing letters during stock trading hours.
GMP Close-out Letter Program Shows Few Benefits After 20 Months
More than 20 months after FDA Commissioner Margaret Hamburg announced with much fanfare that the agency would issue "close-out letters" to companies that had received FDA warning letters once they had addressed the problems inspectors found, the program has yet to fulfill its promise of offering sponsors a reliable, public way of resolving regulatory problems.
GMP Close-out Letter Program Shows Few Benefits After 20 Months
More than 20 months after FDA Commissioner Margaret Hamburg announced with much fanfare that the agency would issue "close-out letters" to companies that had received FDA warning letters once they had addressed the problems inspectors found, the program has yet to fulfill its promise of offering sponsors a reliable, public way of resolving regulatory problems.